Science
Moderna and Merck's personalized mRNA vaccine against melanoma cut the risk of death or recurrence by 42% in a Phase 3 trial, a first for cancer care.
Loading…
Search
No phones and 1 story for “Merck”
Science
Moderna and Merck's personalized mRNA vaccine against melanoma cut the risk of death or recurrence by 42% in a Phase 3 trial, a first for cancer care.